Orchard Capital Management LLC Invests $1.34 Million in Intellia Therapeutics, Inc. $NTLA

Orchard Capital Management LLC purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 79,503 shares of the company’s stock, valued at approximately $1,345,000. Intellia Therapeutics makes up about 1.3% of Orchard Capital Management LLC’s investment portfolio, making the stock its 26th largest position. Orchard Capital Management LLC owned 0.06% of Intellia Therapeutics at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of Intellia Therapeutics by 154.1% during the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after acquiring an additional 55,118 shares during the period. Woodline Partners LP bought a new stake in shares of Intellia Therapeutics in the first quarter valued at $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Intellia Therapeutics by 8.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after buying an additional 38,521 shares during the last quarter. Creative Planning lifted its position in shares of Intellia Therapeutics by 12.9% during the 2nd quarter. Creative Planning now owns 33,102 shares of the company’s stock valued at $310,000 after buying an additional 3,795 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Intellia Therapeutics by 47.4% during the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after acquiring an additional 10,785 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $12.84 on Friday. The stock has a market cap of $1.80 billion, a P/E ratio of -3.82 and a beta of 1.81. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The stock has a 50 day simple moving average of $13.47 and a two-hundred day simple moving average of $13.35.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the company earned ($0.98) earnings per share. The firm’s revenue for the quarter was down 46.4% on a year-over-year basis. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

NTLA has been the subject of several recent research reports. New Street Research set a $25.00 price objective on Intellia Therapeutics in a report on Monday, June 15th. Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Citizens Jmp reiterated a “market outperform” rating and set a $30.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Finally, Wolfe Research cut Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective on the stock. in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $21.15.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.